FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

HIKAL Consensus Forecast

No. of reports in last year
2
No. of analysts
2
Average Consensus Forecast
162
Consensus Potential
2.15%

HIKAL Price Target Potential

BrokerageTargetPotential
Sushil Finance18415.43%
ICICIdirect.com140-11.14%

HIKAL Targets in FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for HIKAL
0% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

HIKAL Ratings

Long term HIKAL rating by FrontPage users
5/5 (2 Ratings)

2 HIKAL share price target reports by brokerages below. See what is analyst's view on HIKAL share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. HIKAL Forum
  3. HIKAL Price Target

HIKAL Share Price Target

HIKAL Share Price Target - Broker Reports - 2020

23-Jun-20
Price @ Call: 127.96
Target: 184
BUY
Although COVID-19 related shutdown hampered the sales of the company in FY20, we believe expertise in API development and growth of crop protection business mainly due to strong client relationship can bring the company back to its previous growth trajectory. Hence, taking the effect of COVID-19 into account we have revised our estimates. We expect revenue in FY21E and FY22E to be around Rs.1,613 Cr and Rs.1889 Cr respectively showing a CAGR of ~12%. PAT and EPS for FY21E and FY22E is expected to be Rs. 98.9 Cr & 8.02 and Rs.146.7 Cr & 11.90. Hikal Ltd remains a fair value proposition with its pharma and crop protection business continuing to expand. Hence, we arrived at a target price of Rs.184 based on ~15X of FY22 EPS in an investment horizon of 17-21 months.
... Read more

HIKAL Share Price Target - Broker Reports - 2019

30-Oct-19
Price @ Call: 117.09
Target: 140
BUY
The hitherto unblemished growth track record was impacted by certain unforeseen one-offs (flood and water cut) besides a scheduled shutdown for capacity expansion. While the management has assured on substantial recouping (if not entire) of the lost business in Q3, Q4, the lack of disclosures of these events has already taken a toll on the stock price. Coming back to earnings, the full year revenue guidance of 5-10% seems difficult. However, going by the capex guidance, things are looking promising for FY21. On the margins front, gross margins are improving due to focus on high margin products. However, the management has to improve on the disclosure front as this is one of the major sources of information for B2B players like Hikal. But for this lacuna, Hikal continues to offer a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. We arrive at a valuation of rs 140 based on 14x FY21E EPS of Rs 11.7.
... Read more
2-Aug-19
Price @ Call: 146.8
Target: 190
BUY
Key takeaways from Q1 numbers were strong growth in crop protection, steady growth in pharma but lower blended level margins that are attributable to a product mix and plant related expenses. The management still remains conservative on the revenue growth guidance front (10-15% in FY20 maintained) as the focus is likely to be on high margin products besides a close watch on capacities. With proven capabilities and management pedigree, we believe Hikal offers a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. We arrive at a valuation of Rs 190 based on 14x FY21E EPS of | 13.6.
... Read more
13-May-19
Price @ Call: 174.7
Target: 205
BUY
For years, the company has been dealing with high profile MNCs like Merck & Co, Bayer, Syngenta, BASF, Pfizer to name a few. With proven capabilities and management pedigree, we believe Hikal offers a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. The company has spent ~| 500 crore over the last five years to augment capacities. After years of volatility in growth, Hikal has been witnessing a relatively stable growth trajectory. We arrive at a valuation of Rs 205 based on 15x FY21E EPS of Rs 13.7.
... Read more
18-Apr-19
Price @ Call: 177.91
Target: 218
BUY
4-Mar-19
Price @ Call: 167.01
Target: 200
BUY
For years, the company has been dealing with high profile MNCs like Merck & Co, Bayer, Syngenta, BASF, Pfizer to name a few. With proven capabilities and management pedigree, we believe Hikal offers a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. The company has spent ~| 500 crore over the last five years to augment capacities. After years of volatility in growth, Hikal has been witnessing a relatively stable growth trajectory. We expect sales, EBITDA, PAT to grow at a CAGR of 15%, 18%, 30%, respectively, in FY19-21E on the back of new launches and better operating leverage. Simultaneously, we also expect a 330 bps RoCE improvement to 17.3% through FY21. We arrive at a valuation of Rs 200 based on 15x FY21E EPS of Rs 13.3.
... Read more

HIKAL Share Price Target - Broker Reports - 2018

12-Oct-18
Price @ Call: 160.62
Target: 190
BUY

HIKAL Share Price Target - Broker Reports - 2017

28-Apr-17
Price @ Call: 141.33
Target: 193.33
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • HIKAL Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3179.58
    Upside Target 2173.62
    Upside Target 1167.53
    Pivot161.57
    Downside Target 1155.48
    Downside Target 2149.52
    Downside Target 3143.43
  • HIKAL Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3189.47
    Upside Target 2174.53
    Upside Target 1165.07
    Pivot150.13
    Downside Target 1140.67
    Downside Target 2125.73
    Downside Target 3116.27
  • HIKAL Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3210.33
    Upside Target 2184.97
    Upside Target 1170.28
    Pivot144.92
    Downside Target 1130.23
    Downside Target 2104.87
    Downside Target 390.18
  • HIKAL Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3173.62
    Upside Target 2169.01
    Upside Target 1166.17
    Pivot161.57
    Downside Target 1156.96
    Downside Target 2154.12
    Downside Target 3149.52
  • HIKAL Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3174.53
    Upside Target 2165.21
    Upside Target 1159.45
    Pivot150.13
    Downside Target 1140.81
    Downside Target 2135.05
    Downside Target 3125.73
  • HIKAL Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3184.97
    Upside Target 2169.67
    Upside Target 1160.22
    Pivot144.92
    Downside Target 1129.62
    Downside Target 2120.17
    Downside Target 3104.87
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020